| Drug Name: | Cytarabine (147-94-4) |
|---|---|
| PubChem ID: | 6253 |
| SMILES: | C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O |
| InchiKey: | UHDGCWIWMRVCDJ-CCXZUQQUSA-N |
| Therapeutic Category: | Anti-Infective Agents, Antimetabolites, Antineoplastic Agents, Antiviral Agents, Immunologic Factors, Immunosuppressive Agents, Noxae |
| Molecular Weight (dalton) | : | 243.219 |
| LogP | : | -2.563 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 8 |
| Hydrogen Bond Donor Count | : | 4 |
| Total Polar Surface Area | : | 130.83 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Cytotoxicity | Hepatocyte growth factor (P14210) | Stimulation of clonogenic acute myeloid leukemia (AML) cells by hematopoietic growth factors (HGF) is capable of enhancing cytosine-arabinoside (Ara-C) cytotoxicity in vitro. [ ADR Type 1 ] | Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells |
| Cytotoxicity | Interleukin-3 (P08700) | IL-3 stimulation enhanced Ara-C incorporation@ which is capable of enhancing cytosine-arabinoside (Ara-C) cytotoxicity in vitro [ ADR Type 5 ] | Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category